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Abstract: Background: Feline coronavirus (FCoV) infection is ubiquitous in multi-cat households.
Responsible for the continuous presence are cats that are chronically shedding a high load of FCoV.
The aim of the study was to determine a possible correlation between FCoV antibody titer and
frequency and load of fecal FCoV shedding in cats from catteries. Methods: Four fecal samples
from each of 82 cats originating from 19 German catteries were examined for FCoV viral loads by
quantitative reverse transcriptase polymerase chain reaction (RT-qPCR). Additionally, antibody titers
were determined by an immunofluorescence assay. Results: Cats with antibodies were more likely to
be FCoV shedders than non-shedders, and there was a weak positive correlation between antibody
titer and mean fecal virus load (Spearman r = 0.2984; p = 0.0072). Antibody titers were significantly
higher if cats shed FCoV more frequently throughout the study period (p = 0.0063). When analyzing
only FCoV shedders, cats that were RT-qPCR-positive in all four samples had significantly higher
antibody titers (p = 0.0014) and significantly higher mean fecal virus loads (p = 0.0475) than cats that
were RT-qPCR-positive in only one, two, or three samples. Conclusions: The cats’ antibody titers
correlate with the likelihood and frequency of FCoV shedding and fecal virus load. Chronic shedders
have higher antibody titers and shed more virus. This knowledge is important for the management
of FCoV infections in multi-cat environments, but the results indicate that antibody measurement
cannot replace fecal RT-qPCR.
Keywords: feline infectious peritonitis (FIP); feline coronavirus (FCoV); carrier; feline enteric
coronavirus (FECV); serology; transmission; multi-cat household
1. Introduction
Feline coronavirus (FCoV) is a viral pathogen infecting cats worldwide. It is highly contagious [1]:
nearly 100% of cats become infected when exposed, usually horizontally via the fecal-oral route [2,3].
Additionally, the virus can persist in excretions in the environment for up to several weeks [4],
rendering indirect transmission, e.g., via caregivers, a possible route of infection. The prevalence of
FCoV in the cat population is very high; this is especially true for multi-cat households, in which
prevalence can be as high as 90% [5–7]. Only about 7–14% of FCoV-infected cats go on to develop
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feline infectious peritonitis (FIP) [8], which arises from the mutation of the avirulent enteric FCoV
(FECV) with a tropism for the gastrointestinal tract to the highly virulent FIP virus (FIPV), with a
tropism for monocytes/macrophages within an infected cat [9,10]. The pathological hallmark of FIP is
a granulomatous vasculitis and perivasculitis [11], which develops as the result of an immunological
process. Subsequent to the infection of monocytes/macrophages and replication of FCoV within these
cells, multiple cytokines, including tumor necrosis factor alpha, and adhesion molecules, are produced
and ultimately lead to increased vascular permeability and the development of pyogranulomas [11–16].
Both healthy FCoV-infected cats and cats suffering from FIP can shed FCoV in their feces [17–19].
Fecal shedding of mutated FCoV in cats with FIP is rare, and if it occurs, this virus is not infectious for
other cats [20].
If a cat becomes infected with FCoV, fecal virus shedding usually begins within one week after
infection [3,21], and in general follows three possible patterns: some cats become chronic FCoV
carriers, and persistently, even in the absence of re-infection, shed the virus for varying times or even
lifelong; some cats will eliminate the infection and stop shedding FCoV, but can become re-infected;
and consequently, the majority of cats shed FCoV intermittently or (more likely) continuously become
re-infected throughout their lives [3,22,23]. It has been shown that young and immunosuppressed
cats shed more virus with their feces than older or healthy cats [3]. Cats infected with feline
immunodeficiency virus, for instance, shed 10–100×more FCoV than healthy age-matched controls [9].
After experimental infection with FCoV, antibodies first appear in the blood after about one to
three weeks [21,23,24]. Antibodies are not effective to clear enteric viral colonization and to prevent
re-infection. Additionally, antibodies do not preclude the development of FIP. In fact, experimental
studies even demonstrated a more rapid and severe course of the disease in cats with pre-existing
antibodies, due to antibody-dependent enhancement [25–28], although this phenomenon most likely
does not occur under field conditions [22]. Moreover, FCoV-infected monocytes/macrophages do not
present viral antigen on their cell surface, thereby avoiding antibody-mediated lysis by the immune
system [29]. Previous studies have proposed a correlation between the antibody titer of a cat and its
fecal FCoV shedding. These studies have found that cats with higher antibody titers are more likely to
be FCoV shedders, whereas cats with lower antibody titers are less likely to shed virus in their feces
and most cats without antibodies do not shed FCoV [3,30,31]. However, the results are controversial,
as some studies did not confirm these findings [32–34]. Additionally, it has been reported that not
all cats with antibodies are virus shedders [32]; only approximately 30% antibody-positive cats shed
FCoV in their feces [35]. Similarly, there are reports of some antibody-negative cats that shed FCoV in
their feces [18,31]. There is only one dissertation, which was not published in a peer-reviewed journal,
suggesting a correlation between the frequency and the amount of fecal FCoV shedding, and between
the antibody titer and the amount of FCoV shedding [36].
For many years, FIP was considered a uniformly fatal disease. Very recently, however, novel
drugs, such as a nucleoside analog, GS-441524, were shown to have antiviral efficacy in cats with
experimental and natural FIP and in cats with asymptomatic FCoV infection [37–40]. Nevertheless,
these medications are not yet commercially available and might not be affordable for all cat owners,
especially for cat breeders and rescue shelters. Additionally, there are serious concerns that its use to
eliminate FCoV infection rather than to treat FIP might give rise to resistant viral mutants. Therefore,
the eradication of FCoV infection in multi-cat households, if at all possible, still widely relies on
hygiene and husbandry measures, the identification of virus carriers and separation of shedders from
non-infected cats [33]. Although this can be achieved by testing repeat fecal samples for FCoV RNA by
quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), such a procedure will prolong
the period in which the shedding status of a cat is unknown [41], since the collection of sequential fecal
samples and analysis by RT-qPCR will take much longer than antibody measurement from one blood
sample. Therefore, an attempt to quickly detect antibodies as an indication of the amount of shedding
has been proposed.
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It was the aim of this study to determine a possible correlation between the FCoV antibody titer
and fecal FCoV shedding in catteries. The questions addressed included (1) whether cats with higher
antibody titers would shed higher concentrations of FCoV with their feces; and (2) whether cats shed
FCoV more frequently throughout the study period and (3) whether cats shedding FCoV in all four
fecal samples collected would have higher antibody titers and shed higher concentrations of FCoV
than cats that shed virus only intermittently. Indeed, the results obtained suggest that in cats from
German catteries, the antibody titer is correlated with mean fecal virus load. Cats with antibodies
were more likely to be FCoV shedders than non-shedders. Cats with higher antibody titers shed FCoV
more frequently and with a higher mean fecal virus load than cats with lower FCoV antibody titers or
without antibodies. Cats shedding FCoV in all four fecal samples had higher FCoV antibody titers
and shed higher concentrations of FCoV than cats shedding FCoV intermittently. However, there
were nine cats without antibodies that shed FCoV. Thus, antibody testing cannot replace fecal testing
by RT-qPCR.
2. Results
Anti-FCoV antibodies were detected in 64 of the 82 cats (78%) included in the study (Figure 1).
All 19 catteries homed at least one cat with antibodies. FCoV RNA could be detected in at least one
of the four fecal samples collected at intervals of 5-30 days by RT-qPCR in 58 of the 82 included cats
(71%), and all 19 catteries homed at least one cat that was shedding FCoV in at least one fecal sample.
 
Figure 1. Antibody titers of cats not shedding feline coronavirus (FCoV) and of cats with one, two,
three, or four fecal samples positive for FCoV RNA by quantitative reverse transcriptase polymerase
chain reaction (RT-qPCR). Fecal samples with weak positive RT-qPCR results were considered positive;
samples below the limit of quantification were considered negative.
Of the 18 cats without detectable antibodies, nine cats (50%) shed FCoV at least once. Of the cats
with antibodies, 20/28 (71%) with an antibody titer of 1:25, 21/26 (81%) with a titer of 1:100, and 8/10
(80%) with a titer of 1:400 shed FCoV at least once. None of the cats had an antibody titer of 1:1600.
Most (71%) of the 24 cats that were not shedding FCoV either did not have antibodies (9/24; 38%) or
only a very low titer of 1:25 (8/24; 33%). Nevertheless, 7/24 (29%) cats that were RT-qPCR-negative in
all four fecal samples had an antibody titer of at least 1:100.
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2.1. Correlation between Mean Fecal FCoV Load and Antibody Titer
Fecal virus load ranged from 2.2 × 106 to 4.5 × 1012 per gram (g) of feces (median 6.8 × 109 per g
feces) in cats shedding FCoV (Table 1). Cats with higher anti-FCoV antibody titers also had significantly
higher mean fecal virus loads. There was a weak positive correlation between the antibody titer and the
calculated mean fecal virus load (mean of all four fecal samples) (Spearman r = 0.2984, 95% confidence
interval 0.07761–0.4913; p = 0.0072).
Table 1. Fecal feline coronavirus (FCoV) load per gram of feces of cats with different antibody titers
detected by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR). Fecal FCoV load
was calculated as the mean of all four fecal samples from each cat. The two cats with only one weak
RT-qPCR-positive or one sample below the limit of quantification and three RT-qPCR-negative fecal
samples each were excluded from analysis.
Antibody Titer Number of Cats Fecal FCoV Load
Negative 8 2.2 × 106–5.0 × 1011 (median 2.6 × 109)
1:25 20 6.4 × 106–8.0 × 1011 (median 1.3 × 1010)
1:100 21 7.4 × 108–1.3 × 1012 (median 1.2 × 1010)
1:400 8 3.4 × 108–2.9 × 1011 (median 2.0 × 1010)
1:1600 0 n. a.
n. a.: not applicable.
2.2. Correlation between Frequency of Fecal FCoV Shedding and Antibody Titer and Mean Fecal FCoV Load
In addition to shedding larger amounts of FCoV with their feces, cats with higher antibody titers
also shed FCoV more frequently. Antibody titers were significantly higher in cats with more frequent
than in cats with less frequent FCoV shedding (p = 0.0063; Figure 1). However, when comparing
the cats in different groups (based on their frequency of FCoV shedding), this difference was only
significant between cats that were RT-qPCR-negative in all four fecal samples and cats that were
RT-qPCR-positive in all four fecal samples (Dunn’s test; p < 0.05). Two cats that were RT-qPCR-positive
in all four fecal samples did not have antibodies and two cats that were RT-qPCR-negative in all four
fecal samples had a high antibody titer of 1:400.
When considering the mean fecal virus load and frequency of FCoV shedding, there was a slight
tendency that cats shedding FCoV more frequently shed higher concentrations of FCoV RNA, but that
association was not significant (p = 0.1323; Table 2).
Table 2. Mean fecal feline coronavirus (FCoV) load per gram of feces of cats with different frequencies
of FCoV shedding detected by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR).
Fecal FCoV load was calculated as the mean of all four fecal samples from each cat. Fecal samples with
weak positive RT-qPCR results were considered positive; samples below the limit of quantification
were considered negative. The two cats with only one weak RT-qPCR-positive or one sample below the
limit of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.
Shedding Frequency Number of Cats Fecal FCoV Load
One sample RT-qPCR-positive 9 2.2 × 106–3.1 × 1011 (median 5.2 × 109)
Two samples RT-qPCR-positive 6 5.1 × 108–4.9 × 1011 (median 3.7 × 109)
Three samples RT-qPCR-positive 5 2.5 × 109–5.5 × 1011 (median 1.1 × 1010)
Four samples RT-qPCR-positive 37 3.4 × 108–1.3 × 1012 (median 2.5 × 1010)
2.3. Correlation between FCoV Shedding in All Four vs. One to Three Samples and Antibody Titer
Fifty-eight of the 82 cats (71%) were positive for FCoV RNA by RT-qPCR in at least one of the four
fecal samples collected. Of those 58 cats, 37 (64%) were RT-qPCR-positive in all four fecal samples.
These 37 cats shedding in all four fecal samples had significantly higher antibody titers than cats that
were RT-qPCR-positive in only one, two, or three fecal samples (p = 0.0014; Table 3).
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Table 3. Numbers of cats with different antibody titers with positive quantitative reverse transcriptase
polymerase chain reaction (RT-qPCR) detecting feline coronavirus (FCoV) RNA in all four (continuous
shedders) or only one to three (non-continuous shedders) fecal samples. Fecal samples with weak
positive RT-qPCR results were considered positive; samples below the limit of quantification were
considered negative.
Antibody Titer Continuous Shedders (% of total) Non-Continuous Shedders (% of total) Total Shedding Cats
Negative 2 (22%) 7 (78%) 9
1:25 12 (63%) 7 (37%) 19
1:100 15 (68%) 7 (32%) 22
1:400 8 (100%) 0 (0%) 8
Total 37 (64%) 21 (36%) 58
Moreover, when comparing shedders with four RT-qPCR-positive fecal samples and shedders
with one to three RT-qPCR-positive fecal samples, shedders with four RT-qPCR-positive fecal samples
shed significantly higher mean fecal virus loads (3.45 × 108–1.31 × 1012 viral copies per g feces, median
2.53 × 1010; p = 0.0475; Figure 2) than shedders with one to three RT-qPCR-positive fecal samples
(2.27 × 106–5.50 × 1011 viral copies per g feces, median 5.47 × 109).
 
Figure 2. Box and whisker plot. Comparison of cats with one to three versus four fecal samples
positive for feline coronavirus (FCoV) RNA by quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR), with cats with four fecal samples positive FCoV RNA by RT-qPCR. Mean fecal
virus load per gram (g) of feces of cats with four RT-qPCR-positive samples was significantly higher
compared to cats with only one, two, or three RT-qPCR-positive samples (p = 0.0475). Mean fecal FCoV
load was calculated as the mean of all four fecal samples from each cat. Fecal samples with weak
positive RT-qPCR results were considered positive; samples below the limit of quantification were
considered negative. The two cats with only one weak RT-qPCR-positive or one sample below the limit
of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.
3. Discussion
The aim of this study was to investigate a possible correlation between FCoV antibody titer and
fecal virus shedding in healthy cats living in German catteries. The majority of antibody-positive
cats in this study (49/64, 77%) shed FCoV in their feces. However, the study also showed that this
assumption is not absolute, since 9/18 (50%) of cats without antibodies also were FCoV shedders and
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2/10 (20%) of the cats with a high antibody titer of 1:400 did not shed FCoV. Previously, only 30%
antibody-positive cats were reported to shed FCoV [30]. A possible reason for this disagreement is
the way in which shedding was confirmed in the two studies. In the present study, FCoV RNA was
detected in fecal samples by RT-qPCR. This technique is very sensitive. In the previously published
study, RT-PCR was not yet available, so the classification of a cat as shedder occurred via its infectivity
to other cats. More precisely, kittens of antibody-positive queens were monitored for the development
of antibodies and it was shown that 38% of the litters developed antibodies, indicating viral shedding
occurred in around 30% of the queens [30]. Of course, this approach is not directly comparable to the
testing of feces by molecular methods such as RT-qPCR, as performed in the present study.
According to previous studies, FCoV antibody titers are significantly higher in cats that shed
FCoV with their feces than in cats that do not shed FCoV [3,30,31]. Additionally, it was proposed
that cats without FCoV antibodies are not shedding FCoV and that, as a consequence, it would be
safe to introduce an antibody-negative cat into a FCoV-free household [3,30,31]. However, a smaller
number of studies reported discordant results, refuting a correlation between FCoV antibody titer
and the likelihood of FCoV shedding [32–34]. Pedersen et al. [3] tried to explain this discrepancy by
different ways of data evaluation. Correlation between antibody titer and fecal virus shedding was
significant when shedding and non-shedding cats were looked at as groups. Conversely, there was a
substantial overlap when evaluating individual cats [3]. This, at least in part, is also true for the cats in
the present study. Most cats with a high antibody titer of 1:400 were shedding FCoV (and shed FCoV
in all four fecal samples), but two cats with a titer of 1:400 did not shed FCoV in any of the four fecal
samples. Even more discrepancy could be seen among the cats without antibodies: 9/18 of the cats
without antibodies shed FCoV at least once during the study period. This is a result that, despite the
initial belief that antibody-negative cats would never shed FCoV [30–32], has been reported in the
literature before [18,34]. It is possible that the contamination of fecal samples by other FCoV-positive
cats had occurred in the same multi-cat household. In order to avoid contamination, rectal swabs
could be used for testing purposes by cat breeders [31], but this would reduce the amount of available
fecal material. Contamination of samples in the laboratory cannot fully be excluded, but seems rather
unlikely given that extensive quality controls were included in the RT-qPCR protocol. More likely,
it is conceivable that serum/plasma samples were obtained early in an infection, at a time before
the cats developed antibodies, but at which they already shed FCoV with their feces. Shedding of
FCoV before the time of antibody development has already been reported in kittens [34]. Since serial
antibody measurements were not performed in the present study, such scenario cannot be confirmed.
Alternatively, the documentation of fecal FCoV shedding in antibody-negative cats could be explained
by localized infection. It is known that FCoV replication can stay confined to the gastrointestinal tract in
some FCoV-infected cats, resulting in fecal FCoV shedding without the development of antibodies [18].
This might also have occurred in the cats in the present study.
Antibody testing and the separation of antibody-negative cats in the past has been suggested
as method to clear FCoV infection from a breeding cattery [42] or prevent the introduction of FCoV
infection into the FCoV-free geographical area of the Falkland Islands [43]. However, as clearly shown
by the results of the present study, although the antibody titer can give an idea on a cat’s shedding
status, a negative antibody titer in a cat does not exclude fecal shedding. Thus, the introduction of cats
into FCoV-free environments on the basis of a negative antibody test still bears the risk of introducing
a FCoV-shedding cat. On the other hand, the separation of all antibody-positive cats might not be
necessary, because not all cats with antibodies shed FCoV with their feces.
The next question to be answered was whether cats with higher antibody titers also shed higher
concentrations of FCoV RNA with their feces. In this study, there was a weak positive correlation
between the quantity of antibodies and the mean fecal virus load determined by RT-qPCR, indicating
that cats with higher antibody titers were more likely to shed FCoV more intensely compared to cats
with low antibody titers and cats without antibodies. It is possible that a higher amount of viral
replication, as demonstrated by a higher fecal virus load, also leads to increased antibody production,
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and thus, higher antibody titers. However, since there is some overlap, this correlation is only weak,
demonstrating that antibody measurement alone is not sufficient to differentiate high intensity from
low intensity shedders. So far, there is only one report, which was not published in a peer-reviewed
journal, that also suggested a correlation between FCoV antibody titer and the intensity of fecal virus
shedding [36]. Clarification of such information, however, is of practical importance, since especially
high intensity shedders are a concern in environments where many cats are housed together in a limited
space. These cats shedding large amounts of FCoV pose a high risk of transmission to non-infected
cats, and in order to reduce infection pressure in multi-cat environments, the contact of non-infected
cats to litter trays of high intensity shedders must be avoided [33,44]. However, the routine practice of
testing four sequential fecal samples or rectal swabs taken one week to one month apart for FCoV by
RT-qPCR, while increasing the likelihood of correctly identifying non-shedders, leads to a prolonged
period of time, in which the shedding status of cats in the multi-cat environment is unknown [31,41].
This is especially problematic in rescue shelters, where new cats with unknown FCoV status are to be
introduced. Antibody titers (for which only one blood sample is necessary), in contrast, are available
much faster and therefore could help to distinguish high intensity from low intensity shedders or cats
not shedding FCoV. The results of the present study indicate that the risk of shedding large amounts of
FCoV will increase with the level of a cat’s antibody titer, and a cat without antibodies most likely will
not shed large amounts of FCoV. This understanding might help to at least estimate whether strict
quarantine measures are indispensable or not for each individual cat. The practice of separating high
intensity shedders, low intensity shedders and non-shedders in a cat population in order to eliminate
FCoV infection is being proposed, but not without controversy [44,45]. It has been suggested that
antibody measurement might be of importance in breeding catteries, in which kittens might be initially
protected from infection by maternally-derived antibodies (MDA), that are transferred by nursing from
antibody-positive queens, but can become infected as soon as MDA wane. Isolation of pregnant queens
before birth and early weaning of kittens at an age of five to six weeks, before the loss of MDA, has
been proposed [30,33]. However, this protocol has been questioned, since the adequate socialization of
isolated kittens is a concern and FCoV infection can occur as early as two weeks of age [46].
After fecal-oral FCoV infection, three possible shedding patterns have been observed. Cats can
shed FCoV intermittently [3,22,23,31,32,47]. Most likely, this is only partially caused by intermittent
fecal excretion, but also by re-infection with either the same or a different FCoV strain throughout
their lives [22]. Some cats will shed FCoV for weeks or months and eventually cease fecal shedding.
Up to 13% of cats will shed FCoV persistently for a prolonged period of time and sometimes even
lifelong [3,22,31,32,47]. The exact percentage of cats following each pattern is unknown and likely
varies depending on the epidemiological situation and virulence of the infecting FCoV strain. In order
to correctly characterize a FCoV-shedding cat for eradication purposes, sequential fecal samples must
be obtained and four fecal samples, collected 5–30 days apart, were obtained from each cat in this
study. Results indicate that cats had significantly higher antibody titers if they shed FCoV more
frequently. When considering the results of the individual cats, it becomes apparent that most cats
(71%) that did not shed FCoV in any fecal sample either did not have antibodies (9/24) or only had
a low antibody titer of 1:25 (8/24), whereas most cats with a high antibody titer of 1:400 (8/10; 80%)
shed FCoV in all four samples. Nevertheless, although there was a tendency for cats shedding FCoV
more frequently (possibly due to continuous re-infection) to have higher antibody titers, again there
was some overlap, and the correlation was only significant for cats shedding in all four fecal samples
compared to non-shedders.
It was also determined whether cats shedding FCoV in all four samples had higher antibody
titers than cats shedding FCoV in only one, two, or three fecal samples. The latter cats probably
eliminated the infection at some point, shed intermittently or became re-infected. In this context, it is
of special interest to evaluate whether measurement of the antibody titer can indicate if a cat likely is
continuously shedding FCoV, and thus, poses a permanent risk of infection to other cats. It could be
shown that, in this population, cats that were RT-qPCR-positive in all four samples had significantly
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higher antibody titers than cats, that were RT-qPCR-positive only intermittently in one, two, or three
fecal samples. Additionally, cats shedding FCoV in all four samples also had significantly higher
mean fecal virus loads than cats shedding only intermittently. This confirms the results of one study
performed as part of a doctoral thesis, which followed 77 FCoV-infected cats over a period of 24 weeks,
and could demonstrate that the amount of FCoV RNA shed was significantly higher with higher
shedding frequency (defined as % of RT-qPCR-positive fecal samples) [36].
Twenty-four cats were RT-qPCR-negative in all four fecal samples, indicating that they persistently
did not shed FCoV. These cats either did not have contact to FCoV, which seems rather unlikely given
the fact that all of the included catteries harbored at least one FCoV-shedding cat and the virus is
highly contagious [7,23,33]. Alternatively, these cats could have been resistant to FCoV. Resistant cats
never shed FCoV and do not develop FCoV antibodies or only very low titers [31]. The mechanism
for this is unknown [46]. Interestingly, however, 15 of the 24 non-shedders in this study did have
antibodies. Mostly, these cats had low antibody titers. A possible explanation for this could be that
the cats had been infected previously, but ceased shedding before the beginning of the study and
antibodies persisted for a longer period of time. The longest period documented in the literature for
which a cat remained antibody-positive after it stopped FCoV shedding was 25 months and decreasing
antibody titers were demonstrated in studies following cats ceasing to shed FCoV over time [31]. It is
possible that antibody titers were in the process of declining in the cats in the present study as well.
This study had some limitations. First, blood samples were obtained from each cat at only one
time point. Therefore, it was impossible to follow the cats and the development of their antibody titers
over time. This would have been especially interesting in cats that ceased to shed virus or in persistent
viral shedders. A second limitation is the fact that most cats were housed very closely, and each cattery
housed at least one cat that shed FCoV. Thus, cross-contamination between the individual cats cannot
fully be excluded, even though cat breeders acted with great caution to separate fecal samples. Thirdly,
in the past, the term chronic FCoV carrier has been used for cats shedding FCoV for at least nine
months [31]. Cats in the present study were followed for a maximum of four months. Therefore, it is
not known whether cats shedding FCoV in all four fecal samples were true FCoV carriers or might
have ceased shedding after the end of the study period.
4. Materials and Methods
The study was performed prospectively and included 82 cats originating from 19 German catteries.
Catteries were distributed all over Germany. A cattery was defined as a cat household with at least
five cats and at least one intact queen for breeding. Breeders collected samples from a variable
non-predefined number of cats in their cattery. Breeds included British Shorthair (n = 24), Bengal
(n = 19), Birman (n = 15), Maine Coon (n = 7), Scottish Fold (n = 7), Norwegian Forest (n = 5), Turkish
Van (n = 3), and Turkish Angora (n = 2). The study protocol was approved by the responsible veterinary
authority (Regierung von Oberbayern; reference number 55.2-1-54-2532.2-14-13).
Cat breeders collected four fecal samples from the cats, at varying time intervals from 5–30 days
between collections. Samples were frozen at−20 °C until examination. All fecal samples were examined
for FCoV load per g of feces by RT-qPCR. A mean fecal virus load was calculated for each cat from
all RT-qPCR-positive samples. For RT-qPCR, total nucleic acid was extracted from fecal samples by
QIAamp DNA Blood BioRobot MDx Kit on an automated Qiagen platform (QIAGEN GmbH, Hilden,
Germany) according to the manufacturer instructions, with slight modifications. The RT-qPCR and
total nucleic acid extraction procedures were adapted from previously published protocols [24,48].
A quantitative real-time PCR based on the 7b gene [48] was performed as a singleplex reaction at a
commercial reference laboratory (IDEXX Laboratories, Ludwigsburg, Germany). Real-time PCR was
run with six quality controls, including: (1) PCR-positive controls (quantitatively;), using synthetic
DNA covering the real-time PCR target region (Integrated DNA Technologies IDT, Coralville, IA,
USA), (2) PCR-negative controls (PCR-grade nuclease free water), (3) negative extraction controls
(extraction positions filled with lysis solution and PCR-grade nuclease free water only), (4) RNA
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pre-analytical internal sample control targeting feline ssr rRNA (18S rRNA) gene complex, (5) a
swab-based environmental contamination monitoring control, and (6) spike-in internal positive control
(using lambda phage DNA). These controls assessed the functionality of the PCR test protocols (1) for
the absence of contamination in the reagents (2) and laboratory (5), the absence of cross-contamination
during the extraction process (3), quality and integrity of the RNA as a measure of sample quality (4),
reverse transcription protocol (5 and 6), and the absence of PCR-inhibitory substances as a carryover
from the sample matrix (6).
The interpretation of RT-qPCR results is demonstrated in Table 4. If RT-qPCR was initially weak
positive (threshold cycle (Ct) > 40), RT-qPCR was repeated in duplicate. Depending on the results
of this duplicate repetitive analysis, results were then categorized (Table 4). Questionable RT-qPCR
results occurred in four cats. The first cat had one fecal sample that was weak positive by RT-qPCR (low
concentrations of FCoV RNA were detected but viral load was below the limit of quantification); the
other three fecal samples of this cat were RT-qPCR-negative. The second cat had two RT-qPCR-negative,
one RT-qPCR-positive and one weak positive fecal sample. The third cat had three RT-qPCR-positive
and one fecal sample below the limit of quantification. The fourth cat had three RT-qPCR-negative and
one fecal sample below the limit of quantification. Weak positive samples were considered positive
for further analysis. Samples below the limit of quantification were considered negative for further
analysis. The two cats with only one weak RT-qPCR-positive or one below the limit of quantification
and three RT-qPCR-negative fecal samples each were excluded from all analyses involving fecal virus
load, since mean fecal virus load could not be determined.




>40 Weak positive (RT-qPCR had to be repeated in duplicate)
No Ct Negative
Ct Value in Duplicate Repetitive Analysis Result
1× < 40 and 1× > 40 Positive
2× > 40 Weak positive 1
1× < 40 and 1× no Ct Questionable positive
1× > 40 and 1× no Ct Below the limit of quantification
2× no Ct Negative
Ct, threshold cycle; 1 Low concentration of feline coronavirus RNA detected.
Additionally, one serum and/or plasma sample was obtained from each of the 82 cats, around
the time of collection of the last fecal sample of each cat. Only a serum sample was available from
68 cats, only a plasma sample was available from 10 cats, and both a serum and a plasma sample
were available from four cats. Serum and/or plasma antibody titers were determined by an indirect
immunofluorescence assay as previously described [49,50], using PD-5 cells (swine origin) infected
with transmissible gastroenteritis virus (Perdue strain). Infected cells were mixed with uninfected cells;
the latter served as internal negative control. Cat samples were tested at dilutions of 1:25, 1:100, 1:400
and 1:1600. The fluorescein isothiocyanate (FITC) conjugated secondary antibody (rabbit anti cat IgG
(H + L), Nordic-MUbio, Sustern, Netherlands; LuBio Sience GmBH, Luzern, Switzerland) was diluted
at 1:40. The serum samples and the conjugate were each incubated at 37 ◦C for 1 h in a humid chamber,
followed by three phosphate buffered saline (PBS) wash steps, and drying of the slide surface with
absorbing paper, preventing the wells from drying out. A positive control (aliquoted serum sample of
a FCoV-antibody-positive field cat) and a negative control (aliquoted serum from a specified pathogen
free FCoV-antibody-negative cat) were run with each slide. The slides were covered with a cover
slide, fixed with a few drops of drops of PBS-Glycerol (1:3) and read using a fluorescence microscope
(Leica DMLB, Leica Microsystems, Heerbrugg, Switzerland). The antigen preparations used to prepare
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the slides were tested for the absence of contaminating viruses by RT-PCR and PCR, as previously
described [51].
The correlation between level of antibody titer and mean fecal virus load was determined by
Spearman’s correlation. Kruskal–Wallis test including Dunn’s post-test was performed in order to
determine a possible correlation between antibody titer and the frequency of virus shedding in an
individual cat. Kruskal–Wallis test was also performed to evaluate a possible correlation between
frequency and amount of fecal virus shedding. Mann–Whitney U test was applied when comparing
cats shedding in all four fecal samples collected and cats shedding in only one to three fecal samples,
in order to determine a possible correlation between the frequency of FCoV shedding and antibody
titer and between the frequency of FCoV shedding and mean fecal virus load. Statistical analysis was
performed using Graph Pad Prism version 5.04 (GraphPad Software, San Diego, CA, USA).
5. Conclusions
In this study, cats with antibodies and especially cats with higher antibody titers were more
likely to shed FCoV; additionally, they shed FCoV significantly more frequently throughout the study
period and had significantly higher mean fecal virus loads than cats with lower antibody titers or
without antibodies. Cats shedding FCoV in all four fecal samples collected had significantly higher
antibody titers and significantly higher mean fecal virus loads than cats shedding FCoV intermittently.
However, it is important to note that even antibody-negative cats shed FCoV, and only 77% of the
antibody-positive cats shed FCoV with their feces. Therefore, the measurement of the antibody titer
can help in managing FCoV infection in catteries or multi-cat households, but cannot replace the
examination of fecal samples by RT-qPCR. RT-qPCR and antibody titer taken together can give a more
reliable picture of the status of an individual cat than each test alone.
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